226 related articles for article (PubMed ID: 32639460)
21. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
Banniettis N; Wysocki J; Szenborn L; Phongsamart W; Pitisuttithum P; Rämet M; Richmond P; Shi Y; Dagan R; Good L; Papa M; Lupinacci R; McFetridge R; Tamms G; Churchill C; Musey L; Bickham K;
Vaccine; 2022 Oct; 40(44):6315-6325. PubMed ID: 36150974
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States.
Payton T; Girgenti D; Frenck RW; Patterson S; Love J; Razmpour A; Sidhu MS; Emini EA; Gruber WC; Scott DA
Pediatr Infect Dis J; 2013 Aug; 32(8):871-80. PubMed ID: 23584582
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial.
Idoko OT; Mboizi RB; Okoye M; Laudat F; Ceesay B; Liang JZ; Le Dren-Narayanin N; Jansen KU; Gurtman A; Center KJ; Scott DA; Kampmann B; Roca A
Vaccine; 2017 May; 35(24):3256-3263. PubMed ID: 28479175
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
[TBL] [Abstract][Full Text] [Related]
26. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.
Quinn CT; Wiedmann RT; Jarovsky D; Lopez-Medina E; Rodriguez HM; Papa M; Boggio G; Shou Q; Dagan R; Richmond P; Feemster K; McFetridge R; Tamms G; Lupinacci R; Musey L; Bickham K
Blood Adv; 2023 Feb; 7(3):414-421. PubMed ID: 36383730
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China.
Zhu F; Hu Y; Li J; Ye Q; Young MM; Zhou X; Chen Z; Yan B; Liang JZ; Gruber WC; Giardina PC; Scott DA
Pediatr Infect Dis J; 2016 Sep; 35(9):999-1010. PubMed ID: 27254028
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
Greenberg D; Hoover PA; Vesikari T; Peltier C; Hurley DC; McFetridge RD; Dallas M; Hartzel J; Marchese RD; Coller BG; Stek JE; Abeygunawardana C; Winters MA; MacNair JE; Pujar NS; Musey L
Vaccine; 2018 Oct; 36(45):6883-6891. PubMed ID: 30244873
[TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
[TBL] [Abstract][Full Text] [Related]
33. An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants.
Mt-Isa S; Chumbley JR; Crawford EL; Banniettis N; Buchwald UK; Weaver J; Weiss T
Expert Rev Vaccines; 2023; 22(1):906-917. PubMed ID: 37846456
[TBL] [Abstract][Full Text] [Related]
34. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
Rodgers GL; Esposito S; Principi N; Gutierrez-Brito M; Diez-Domingo J; Pollard AJ; Snape MD; Martinón-Torres F; Gruber WC; Patterson S; Thompson A; Gurtman A; Paradiso P; Scott DA
Vaccine; 2013 Oct; 31(42):4765-74. PubMed ID: 23965217
[TBL] [Abstract][Full Text] [Related]
35. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).
Severance R; Schwartz H; Dagan R; Connor L; Li J; Pedley A; Hartzel J; Sterling TM; Nolan KM; Tamms GM; Musey LK; Buchwald UK
Hum Vaccin Immunother; 2022 Dec; 18(1):1-14. PubMed ID: 34726574
[No Abstract] [Full Text] [Related]
36. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
38. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY
PLoS One; 2015; 10(12):e0144739. PubMed ID: 26658902
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China.
Zhu F; Hu Y; Li J; Ye Q; Young MM; Liang JZ; Gruber WC; Giardina PC; Scott DA
Pediatr Infect Dis J; 2019 Nov; 38(11):1150-1158. PubMed ID: 31626050
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
